Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback